teladoc glp-1 receptor agonists weight management diabetes treatments New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within Efficacy and Safety of Glucagon-Like

Failure to follow these instructions for use could result in an over delivery or under delivery of insulin

Vasu P, Dorairaj EA, Weinreb RN, Huang AS, Dorairaj SK

GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

Its worth noting that retatrutides safety profile appears broadly consistent with other peptide-based treatments like semaglutide and tirzepatide, which also carry gastrointestinal considerations

In a recent joint statement, FDA and EMA agree that concerns regarding a causal association between incretin-mimetic drugs and pancreatitis or pancreatic cancer are inconsistent with the available evidence [85]

History of pancreatitis : GLP-1 agonists may increase the risk of pancreatitis in some individuals